Apricus Biosciences Inc (APRI):企業のM&A・提携動向(医療分野)

◆英語タイトル:Apricus Biosciences Inc (APRI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:GDPH62310D
◆発行会社(調査会社):GlobalData
◆発行日:2017年2月17日
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:米国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Apricus Biosciences Inc (Apricus) develops and commercializes pharmaceutical products indicated for the treatment of various therapeutic classes including male and female sexual health. Its commercial product portfolio includes, Vitaros, a vasodilator to treat erectile dysfunction. Apricus’ product pipeline consists of RayVa, product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon; and Femprox, an alprostadil-based cream product candidate being developed for the treatment of female sexual arousal disorder. The company develops these products using its proprietary permeation enhancement technology, namely, NexACT, designed to enhance delivery of an active drug to the patient. It operates along with its subsidiaries in British Virgin Islands, and the US. Apricus is headquartered in San Diego, California, the US.

Apricus Biosciences Inc (APRI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Apricus Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Apricus Biosciences Inc, Medical Devices Deals, 2011 to YTD 2017 11
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Apricus Biosciences Acquires Remaining 50% Stake Of Rights To PrevOnco From Innovus Pharma 15
Apricus Biosciences Completes Acquisition Of NitroMist Rights From NovaDel Pharma For US$0.2 Million 15
Venture Financing 16
Apricus Biosciences Raises USD10 Million in Venture Financing 16
Partnerships 18
Apricus Biosciences Extends Distribution Agreement with Ferring Pharma 18
Apricus Biosciences Enters Into Co-Promotion Agreement With PediatRx For GRANISOL And AQUORAL 19
Licensing Agreements 20
Apricus Biosciences Enters into Licensing Agreement with Allergan 20
Apricus Expands Licensing Agreement with Hexal for Vitaros 21
Apricus Biosciences Enters into Licensing Agreement with Forendo Pharma for Fispemifene 22
Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 23
Apricus Biosciences Expands Licensing Agreement With Hexal For Vitaros 24
Apricus Biosciences Enters Into Licensing Agreement With Laboratoires Majorelle For Vitaros 25
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 26
Sandoz Amends its Licensing Agreement with Apricus Biosciences for Vitaros 27
Apricus Biosciences Enters Into Licensing Agreement With Elis Pharma For MycoVa 28
Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 29
Apricus Biosciences Enters Into Licensing Agreement With Stellar Pharma For MycoVa 30
Apricus Biosciences Enters Into Licensing Agreement with Aralez Pharma 31
Apricus Biosciences Enters Into Licensing Agreement With Neopharm For Vitaros 32
Apricus Biosciences Enters Into Licensing Agreement With Elis Pharma For Vitaros 33
Equity Offering 34
Apricus Biosciences Raises USD3.7 Million in Registered Direct Offering 34
Apricus Biosciences to Raise up to USD7 Million in Private Placement of Shares 35
Apricus Biosciences Raises USD7.8 Million in Second and Final Tranche of Private Placement of Shares and Warrants 37
Apricus Biosciences Raises USD2.2 Million in First Tranche of Private Placement of Shares and Warrants 38
Apricus Biosciences to Raise USD11 Million in Private Placement of Shares and Warrants 40
Apricus Biosciences Completes First Tranche of Private Placement of Shares for USD2 Million 41
Apricus Biosciences Completes Public Offering Of Shares For US$17 Million 42
Apricus Biosciences Announces Private Placement Of Shares For US$17.2 Million 43
Apricus Biosciences Completes Public Offering Of Units For US$20 Million 44
Asset Transactions 46
Biocodex Acquires Rights To Totect, Anthracycline Extravasation Medicine, From Apricus Biosciences 46
Mist Pharma Acquires Rights To NitroMist From Apricus Biosciences 47
Acquisition 48
Apricus Biosciences Completes Acquisition Of Finesco For Up To US$11 Million 48
Apricus Biosciences Completes Acquisition Of Topotarget USA 49
Biotox Sciences Acquires Bio-Quant From Apricus Biosciences 50
Apricus Biosciences Inc – Key Competitors 52
Key Employees 53
Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Apricus Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Apricus Biosciences Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Apricus Biosciences Inc, Medical Devices Deals, 2011 to YTD 2017 11
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Apricus Biosciences Acquires Remaining 50% Stake Of Rights To PrevOnco From Innovus Pharma 15
Apricus Biosciences Completes Acquisition Of NitroMist Rights From NovaDel Pharma For US$0.2 Million 15
Apricus Biosciences Raises USD10 Million in Venture Financing 16
Apricus Biosciences Extends Distribution Agreement with Ferring Pharma 18
Apricus Biosciences Enters Into Co-Promotion Agreement With PediatRx For GRANISOL And AQUORAL 19
Apricus Biosciences Enters into Licensing Agreement with Allergan 20
Apricus Expands Licensing Agreement with Hexal for Vitaros 21
Apricus Biosciences Enters into Licensing Agreement with Forendo Pharma for Fispemifene 22
Apricus Biosciences Enters Into Licensing Agreement With Recordati For Vitaros 23
Apricus Biosciences Expands Licensing Agreement With Hexal For Vitaros 24
Apricus Biosciences Enters Into Licensing Agreement With Laboratoires Majorelle For Vitaros 25
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 26
Sandoz Amends its Licensing Agreement with Apricus Biosciences for Vitaros 27
Apricus Biosciences Enters Into Licensing Agreement With Elis Pharma For MycoVa 28
Apricus Biosciences Enters Into Licensing Agreement With Abbott Labs For Vitaros 29
Apricus Biosciences Enters Into Licensing Agreement With Stellar Pharma For MycoVa 30
Apricus Biosciences Enters Into Licensing Agreement with Aralez Pharma 31
Apricus Biosciences Enters Into Licensing Agreement With Neopharm For Vitaros 32
Apricus Biosciences Enters Into Licensing Agreement With Elis Pharma For Vitaros 33
Apricus Biosciences Raises USD3.7 Million in Registered Direct Offering 34
Apricus Biosciences to Raise up to USD7 Million in Private Placement of Shares 35
Apricus Biosciences Raises USD7.8 Million in Second and Final Tranche of Private Placement of Shares and Warrants 37
Apricus Biosciences Raises USD2.2 Million in First Tranche of Private Placement of Shares and Warrants 38
Apricus Biosciences to Raise USD11 Million in Private Placement of Shares and Warrants 40
Apricus Biosciences Completes First Tranche of Private Placement of Shares for USD2 Million 41
Apricus Biosciences Completes Public Offering Of Shares For US$17 Million 42
Apricus Biosciences Announces Private Placement Of Shares For US$17.2 Million 43
Apricus Biosciences Completes Public Offering Of Units For US$20 Million 44
Biocodex Acquires Rights To Totect, Anthracycline Extravasation Medicine, From Apricus Biosciences 46
Mist Pharma Acquires Rights To NitroMist From Apricus Biosciences 47
Apricus Biosciences Completes Acquisition Of Finesco For Up To US$11 Million 48
Apricus Biosciences Completes Acquisition Of Topotarget USA 49
Biotox Sciences Acquires Bio-Quant From Apricus Biosciences 50
Apricus Biosciences Inc, Key Competitors 52
Apricus Biosciences Inc, Key Employees 53
Apricus Biosciences Inc, Subsidiaries 54

List of Figures
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Apricus Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Apricus Biosciences Inc, Medical Devices Deals, 2011 to YTD 2017 11

★海外企業調査レポート[Apricus Biosciences Inc (APRI):企業のM&A・提携動向(医療分野)]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fuso Pharmaceutical Industries Ltd (4538):企業財務及び戦略的SWOT分析
    Summary Fuso Pharmaceutical Industries Ltd (Fuso Pharma) is a biotechnology company that develops and distributes therapeutics and medical tools. The company offers products such as dialysates for artificial kidneys and glucose injectables. It also provides heparin Na syringe, sublood BSG, i-STAT 1, …
  • Ryder System, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Ryder System, Inc. Mergers and …
  • Ginza Project:企業の戦略・SWOT・財務分析
    SummaryGinza Project - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings …
  • Panasonic Healthcare Co., Ltd.:企業のM&A・提携動向(医療機器分野)
    Summary Panasonic Healthcare Co., Ltd. (Panasonic Healthcare) is a medical device company. The company manufactures precision biomedical equipment. It offers refrigeration compressor design, superior ultra-low and cryogenic freezers, refrigerators, incubators and environmental chamber. Panasonic Hea …
  • PATH (Program for Appropriate Technology in Health):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' PATH (Program for Appropriate T …
  • Associated Banc-Corp.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Associated Banc-Corp. Mergers a …
  • OM Holdings, Ltd.:企業の戦略・SWOT・財務分析
    SummaryOM Holdings, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findi …
  • Estel Technologies Pvt. Ltd:企業の戦略的SWOT分析
    Estel Technologies Pvt. Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • China General Technology (Group) Holding Ltd:企業の戦略・SWOT・財務情報
    China General Technology (Group) Holding Ltd - Strategy, SWOT and Corporate Finance Report Summary China General Technology (Group) Holding Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Australian Unity Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Australian Unity Limited Merger …
  • Total E&P Norge AS(石油・ガス分野):企業M&A動向
    Summary Total E&P Norge AS (Total Norge) is an oil and gas company. The company operates, explores, research and produces oil and gas on the Norwegian Continental Shelf. It has its activities in the North Sea, the Norwegian Sea and the Barents Sea. Total Norge's research area specializes in flow per …
  • ActiveCare Inc (ACAR):企業のM&A・提携動向(医療分野)
    Summary ActiveCare Inc (ActiveCare) is a diabetes monitoring products and wellness services for self-insured employers. The company provides monitoring component to traditional disease management and wellness solutions. Its solutions include diabetes supplies, online web-based administrative tools, …
  • Trican Well Service Ltd (TCW):石油・ガス:M&Aディール及び事業提携情報
    Summary Trican Well Service Ltd (Trican) is an oilfield services company, which provides specialized products, equipment, services and technology for use in the drilling, completion, stimulation and reworking of oil and gas wells. Its specialized services comprise fracturing, cementing, coiled tubin …
  • Jilin Qifeng Chemical Fiber Co., Ltd. (549):企業財務及び戦略的SWOT分析
    Summary Jilin Qifeng Chemical Fiber Co., Ltd. (Jilin Qifeng) is a chemical company that manufactures PAN-based fibers. The company provides fiber products such as gel dyed acrylic fiber, anti-pill acrylic fiber, gel dyed acrylic fiber, acrylic top, acrylic staple fiber, acrylic tow and others. It ad …
  • Oi S.A. (OIBR4):企業の財務・戦略的SWOT分析
    Oi S.A. (OIBR4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Infor Global Solutions Inc:企業の戦略的SWOT分析
    Infor Global Solutions Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • KfW Bankengruppe:企業のM&A・提携・投資分析
    KfW Bankengruppe - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's KfW Bankengruppe Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Metorex Ltd:企業の戦略・SWOT・財務情報
    Metorex Ltd - Strategy, SWOT and Corporate Finance Report Summary Metorex Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • VisionQuest Biomedical LLC:企業の製品パイプライン分析2018
    Summary VisionQuest Biomedical LLC (VisionQuest) is a medical device company that develops medical imaging tools for the diagnostic services. The company’s products include eyestar, DR-RACS, and neurotherm. Its eyestar product is a total eye disease screening program package, DR-RACS is an automated …
  • African Development Bank Group:電力:M&Aディール及び事業提携情報
    Summary African Development Bank Group (AfDB) is a development finance institution. It promotes social and economic development by providing loans, grants, guarantees, equity investments and technical assistance in its regional member countries. The constituent institutions of the bank include The A …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆